Table 1.
Summary of articles included
| Paper | Treatment Dosing and treatment schedule Median number of cycles |
N | Age Median (range) |
ECOG PS | IPSS | Median Time of follow-up in months (range) |
Median OS in months (95% CI) |
|---|---|---|---|---|---|---|---|
| Fenaux et al. (AZA-001) 1 |
Azacitidine 75 mg/m2 for 7 days every 28 days 4 cycles (IQR 4–15) |
179 | 69 (42–83) | 0: 44% 1: 48% 2: 7% NA: 1% |
Low: 0% Int-1: 3% Int-2: 43% High: 46% |
21.1 (IQR 15–27) |
24.5 (9.9–not reached) |
| Garcia-Manero et al. 12 | Azacitidine + Placebo 75 mg/m2 for 7 days every 28 days Median number of cycles not shown: 69% received ≥ 5 cycles |
51 | 69 (43–83) | 0: 31% 1: 61% 2: 0% A: 8% |
Low: 0% Int-1: 0% Int-2: 67% High: 33% |
15 | 19 |
| Sekeres et al. 13 |
Azacitidine 75 mg/m2 for 7 days every 28 days 6 cycles |
92 | 69 (42–88) | 0: 31% 1: 59% 2: 10% NA: 0% |
Low: 3% Int-1: 28% Int-2: 45% High: 23% |
23 (1–43) | 15 |
| Silverman et al.14 | Azacitidine 75 mg/m2 for 7 days every 28 days Median number of cycles not shown, response was assessed after the fourth cycle |
99 | 69 (31–92) | Not provided | Low: 2% Int-1: 26% Int-2: 11% High: 9% |
Not provided | 20 (16–26) |
ECOG PS Eastern Cooperative Oncology Group Performance Status, IPSS International Prognostic Scoring System, NA not available, IQR interquartile range